Primary Central Nervous System Lymphoma in Adults

A multidisciplinary team works together to provide you with personalized care for primary central nervous system lymphoma. This rare, fast-growing type of non-Hodgkin lymphoma can start in the brain, eyes, spinal cord, or meninges, which are the layers of tissue that cover and protect the brain and spinal cord. We use the newest genetic tests to determine what therapies are best for you. Your treatment plan may include chemotherapy, targeted drugs, and radiation therapy. You may also be eligible to participate in clinical trials, which offer access to promising new medications.

Clinical Trials and Research Studies

Phase 3

A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727 IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1(NF1)

Learn More

Phase 3

ACNS1833: A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727 IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)

Learn More

Phase 2

A PHASE II RANDOMIZED TRIAL OF PROTON VS. PHOTON THERAPY (IMRT) FOR COGNITIVE PRESERVATION IN PATIENTS WITH IDH MUTANT LOW TO INTERMEDIATE GRADE GLIOMAS

Learn More

Phase 2

A phase II open-label single arm trial of nivolumab ipilimumab and short-course radiotherapy in adults with newly diagnosed MGMT unmethylated glioblastoma

Learn More